An RNA expression panel measures the activity of a selected group of genes in a tissue sample. Instead of asking whether a DNA mutation is present, it estimates how much messenger RNA is being produced from each included gene. A laboratory then combines those measurements—often with a validated mathematical algorithm—to create a recurrence score, molecular subtype, risk category, treatment-response estimate, or other clinically defined result.
These panels are used most often in cancer care. In selected breast, prostate, melanoma, thyroid, and other tumors, an expression profile may add information beyond tumor size, grade, lymph-node status, receptor testing, and routine pathology. It may help estimate the chance of recurrence or whether a particular treatment is likely to provide enough benefit to justify its risks. The test does not diagnose every cancer, detect all mutations, or reveal a person’s inherited cancer susceptibility. Its value depends on using the exact assay in the patient population and treatment setting for which it was validated.
- RNA expression panels measure gene activity in a specific sample, usually tumor tissue, rather than scanning inherited DNA for cancer-risk variants.
- Results are commonly reported as a score or risk category, and cutoffs are unique to each commercial or laboratory-developed assay.
- A high-risk score does not mean recurrence is certain, while a low-risk score does not reduce risk to zero.
- The score must be combined with age, tumor stage, grade, receptor status, lymph nodes, and treatment options before making a clinical decision.
- Poor RNA quality or too little tumor can lead to an invalid result, especially in small or heavily damaged tissue samples.
Table of Contents
- What an RNA Expression Panel Measures
- How the Laboratory Creates an Expression Score
- Where Expression Panels Are Used in Cancer Care
- Prognostic, Predictive, and Diagnostic Information
- How to Read Low, Intermediate, and High Results
- Sample Quality, Accuracy, and Limitations
- Questions to Ask Before Ordering the Test
- Using the Result in a Treatment Plan
What an RNA Expression Panel Measures
Genes are segments of DNA that contain instructions for making functional products. When a gene is active, the cell transcribes part of its DNA into RNA. Messenger RNA, or mRNA, carries the information used to make a protein. Measuring mRNA provides a snapshot of which biological programs are active in the tested cells.
An expression panel may include genes involved in cell division, hormone signaling, immune activity, invasion, DNA repair, stromal response, or other pathways relevant to the disease. It usually also includes reference genes used to normalize the measurements and control for differences in sample input.
The panel does not measure every gene. It analyzes a fixed set chosen during test development. The laboratory may use quantitative reverse-transcription PCR, a hybridization-based platform, a microarray, or targeted RNA sequencing. Each method converts gene-specific signal into numerical expression values.
Those raw values are rarely shown as a simple list on the final report. An algorithm weighs or combines them to generate a clinically validated output. The report might provide:
- a continuous recurrence score;
- a low, intermediate, or high genomic-risk category;
- a molecular subtype;
- an estimate of distant recurrence over a stated period;
- a probability of an event under a particular treatment plan;
- an estimate of treatment benefit;
- a classification linked to surveillance or surgical decisions.
The phrase “cancer risk” can be confusing. Most tumor expression panels estimate the behavior of an already diagnosed cancer, such as recurrence or metastasis risk. They do not usually estimate the chance that a healthy person will develop cancer. That inherited-risk question is addressed by germline genetic testing of DNA from blood, saliva, or another non-tumor sample.
Expression is also dynamic. It can change with tissue type, inflammation, oxygen level, medications, treatment exposure, and the mixture of tumor and normal cells. A result therefore belongs to the specific specimen and time point tested. It is not a permanent personal genotype.
How the Laboratory Creates an Expression Score
The process begins with specimen review. A pathologist confirms the diagnosis, identifies the relevant tumor area, estimates tumor content, and may mark tissue for macrodissection. Most clinical panels use tissue removed during biopsy or surgery. Formalin-fixed, paraffin-embedded blocks are common because they are routinely stored by pathology laboratories.
RNA is less stable than DNA. Formalin, storage time, heat, enzymes, and tissue handling can fragment it. Clinical assays are designed to work with partially degraded RNA, often by measuring short target regions, but every test has minimum quality and quantity requirements.
A typical workflow includes:
- Tissue selection: The laboratory identifies invasive tumor or another required component and avoids necrosis, in situ disease, or excessive normal tissue when possible.
- RNA extraction: RNA is isolated from thin tissue sections or curls cut from the block.
- Quality checks: The laboratory assesses yield, amplifiability, and control-gene performance. Some tests do not require intact full-length RNA because the targets are short.
- Expression measurement: The platform measures each panel gene using RT-qPCR, hybridization probes, microarray features, or sequencing reads.
- Normalization: Target signals are adjusted against reference genes and internal controls.
- Algorithmic calculation: A locked formula converts normalized values into a score or category.
- Quality review: The laboratory checks whether required controls and acceptance criteria passed before issuing the report.
The algorithm is part of the test. Two panels can measure overlapping genes yet produce different results because they use different genes, weights, reference populations, endpoints, and cutoffs. One assay may predict distant recurrence at 10 years with endocrine therapy, while another may classify tumor biology or estimate benefit from extended therapy.
A score should not be transferred into another assay’s category. For example, a numerical value of 20 may be low in one system, intermediate in another, or meaningless in a third. The report’s test name, intended population, and interpretation are essential.
Some panels incorporate clinicopathologic information into a combined model. Others provide a molecular score that clinicians later combine with age, tumor size, grade, lymph nodes, and treatment factors. Both approaches can be useful, but the report should make clear whether the quoted risk is molecular-only or integrated.
Where Expression Panels Are Used in Cancer Care
Expression panels have the strongest established roles in selected early-stage cancers where routine findings leave uncertainty about the likely benefit of additional treatment.
Early hormone receptor–positive breast cancer
This is the most familiar clinical use. Several validated multigene assays estimate recurrence risk in hormone receptor–positive, HER2-negative early breast cancer. Depending on the assay, menopausal status, age, lymph-node involvement, and treatment setting, the result may help determine whether adjuvant chemotherapy is likely to add meaningful benefit to endocrine therapy.
The tests are not interchangeable. Some have predictive evidence for chemotherapy benefit in defined groups; others are primarily prognostic. Some estimate late recurrence or potential benefit from extended endocrine therapy. Professional guidelines specify which assays may be used in particular node-negative or node-positive populations.
A score cannot override clear indications or contraindications. Tumor stage, lymph-node burden, receptor status, comorbidities, patient preference, and the absolute size of possible benefit remain important. A tumor genomic test that searches DNA mutations answers a different question from an RNA recurrence assay.
Prostate cancer
Prostate expression panels may estimate adverse pathology, metastasis, disease-specific mortality, or recurrence after treatment. They can be considered alongside prostate-specific antigen, Gleason grade group, clinical stage, imaging, biopsy volume, age, and life expectancy.
Potential uses include refining active-surveillance discussions, clarifying treatment intensity, or estimating risk after surgery. Evidence and guideline support vary by assay and clinical scenario. A score should not substitute for adequate staging or a complete pathology review.
Melanoma
Gene expression profiles have been developed to estimate recurrence, metastasis, or sentinel lymph-node risk in cutaneous melanoma. These tests may add prognostic information, but their role in changing surveillance, sentinel-node biopsy, or adjuvant treatment remains more debated than the established breast-cancer uses. Standard staging features such as Breslow thickness, ulceration, mitotic activity, and nodal status remain central.
Thyroid nodules and thyroid cancer
Expression classifiers can help evaluate indeterminate thyroid fine-needle aspiration samples. Some aim to identify a benign-like expression pattern and reduce unnecessary surgery; others combine RNA expression with DNA alterations to estimate malignancy risk or tumor type.
These are often called molecular classifiers rather than recurrence panels. Their performance depends on the cytology category, disease prevalence, sample adequacy, and local clinical practice. A benign classifier result lowers but does not eliminate cancer risk.
Other cancers and immune signatures
Expression assays are being used or studied in colon, lung, bladder, kidney, uveal melanoma, hematologic malignancies, and other tumors. Immune-expression signatures may support treatment selection in specific settings. Some are standard biomarkers; others remain investigational.
A clinically available test is not automatically useful for every patient with that cancer. The evidence must match the tumor subtype, stage, treatment decision, and endpoint.
Prognostic, Predictive, and Diagnostic Information
Three terms describe different forms of clinical value.
Prognostic information estimates the likelihood of an outcome regardless of a specific treatment. A prognostic panel may separate tumors into lower and higher recurrence-risk groups. This helps describe the disease’s expected behavior but does not necessarily show that one group benefits more from a particular therapy.
Predictive information estimates whether the relative or absolute benefit of a treatment differs according to the test result. A predictive assay can help identify patients more or less likely to benefit from chemotherapy, endocrine therapy, immunotherapy, or another intervention. Strong predictive evidence usually comes from prospective trials or carefully validated analyses of randomized trial specimens.
Diagnostic or classification information helps determine what the lesion is. A thyroid expression classifier, for example, may refine the probability that an indeterminate nodule is benign or malignant. A lymphoma expression assay may help classify a molecular subtype.
A single panel can provide more than one type of information, but the claims must be validated separately. A test that predicts recurrence is not automatically proven to predict chemotherapy benefit. A test that distinguishes tumor subtypes may not be validated for surveillance intensity.
Clinical validity asks whether the score is associated with the outcome. Clinical utility asks whether using it improves decisions or patient outcomes. Utility can include safely avoiding unnecessary chemotherapy, choosing a more effective treatment, reducing surgery, or focusing surveillance. A statistically significant association is not enough if the score does not change care.
The risk estimate also depends on treatment. A 10-year recurrence estimate may assume that the patient receives five years of endocrine therapy. It should not be read as untreated natural history. If the actual treatment differs, the quoted percentage may no longer apply directly.
Absolute benefit matters more than category alone. A treatment that reduces relative risk by a similar proportion can produce a much larger absolute benefit in a higher-risk patient. Clinicians weigh that benefit against toxicity, competing health risks, fertility concerns, quality of life, and patient priorities.
How to Read Low, Intermediate, and High Results
Expression reports may use a number, category, percentile, graph, or probability. Start by identifying the intended use and population printed on the report.
| Result format | What it may represent | How to interpret it safely |
|---|---|---|
| Continuous score | Algorithmic measure across a numerical range | Use assay-specific thresholds and evidence; do not compare with another panel |
| Low/intermediate/high risk | Groups based on outcome rates in validation studies | Risk is reduced or increased, not absent or certain |
| Percent recurrence estimate | Estimated outcome over a stated period under specified treatment | Check time horizon, treatment assumption, confidence interval, and population |
| Molecular subtype | Expression pattern resembling a biological class | Subtype may complement but not replace standard pathology markers |
| Predicted treatment benefit | Estimated absolute or relative effect of a therapy | Confirm that evidence applies to the patient’s age, stage, nodes, and treatment setting |
A low-risk result usually means that patients with similar tumors had a lower event rate in the validation data. It does not guarantee cure. A high-risk result means the tumor’s expression pattern resembles cancers with higher event rates; it does not mean recurrence is inevitable.
Intermediate categories require special attention. Some assays have updated cutoffs after large trials, and the clinical meaning may depend on age or menopausal status. The clinician should use the current interpretation rather than an old online chart.
A report may include a confidence interval around the risk estimate. This interval shows uncertainty in the model and data. A quoted 10% risk is not a precise prediction for one individual. Pathology sampling, biological variation, and unmeasured factors add further uncertainty.
Discordance can occur between molecular and clinical risk. A small, low-grade tumor may receive a higher expression score, or a larger, higher-grade tumor may receive a low score. The discrepancy is not necessarily an error. It indicates that morphology and gene activity capture different aspects of tumor biology. Integrated tools and multidisciplinary review can help resolve how much weight to give each.
Sample Quality, Accuracy, and Limitations
Expression testing is analytically reliable when the sample meets requirements and the assay is used within its validated scope. Important limitations remain.
Tumor heterogeneity means different areas can contain different proportions of tumor, immune cells, stroma, necrosis, and in situ disease. A small biopsy may not represent the entire tumor. Macrodissection improves tumor enrichment but cannot remove all biological variation.
Pre-analytic factors include time to fixation, fixation duration, tissue age, storage, decalcification, and RNA degradation. Bone samples treated with strong acid may be unsuitable. Very small needle biopsies can be exhausted by routine diagnostic testing before expression analysis is ordered.
Common reasons for test failure include:
- insufficient invasive tumor;
- too little RNA;
- degraded or chemically damaged RNA;
- control-gene values outside the accepted range;
- an incorrect specimen or block;
- contamination with another tissue;
- a tumor type outside the assay indication.
Analytical reproducibility does not guarantee clinical usefulness. The algorithm may produce the same score repeatedly, yet the score may not be validated for a younger patient, a rare histologic subtype, extensive nodal disease, prior treatment, or metastatic cancer.
Expression panels do not identify every actionable DNA mutation, fusion, hereditary variant, or resistance mechanism. Some RNA tests can detect fusions, but a recurrence panel generally measures expression rather than performing a broad RNA sequencing test.
Scores can be affected by neoadjuvant treatment. Many assays were validated on untreated surgical tissue. A post-treatment specimen may reflect therapy-induced changes and may not fit the intended use. The ordering team should select the correct pre-treatment or surgical sample according to assay guidance.
Population representation matters. Validation cohorts may underrepresent certain ancestries, ages, tumor subtypes, or comorbidity patterns. A model can remain useful while carrying greater uncertainty for groups that were less well represented.
Questions to Ask Before Ordering the Test
An expression panel is most useful when its result can change a real decision. Ordering after the treatment choice is already clear may add cost without benefit.
Ask the oncology team:
- What decision will this test help make?
- Is the assay recommended for this tumor type, stage, receptor status, and lymph-node category?
- Is the result prognostic, predictive, diagnostic, or a combination?
- Was the assay validated for my age or menopausal status?
- Does prior chemotherapy, radiation, endocrine therapy, or immunotherapy affect eligibility?
- Which tissue block will be used, and is enough tumor present?
- What happens if the result is intermediate or technically unsuccessful?
- How much could the result change the estimated absolute treatment benefit?
- Will insurance cover the test, and is prior authorization required?
Most tests use archived tissue, so the patient usually does not need another biopsy. The pathology laboratory sends the selected block or unstained slides to the testing laboratory. The block is often returned after testing.
Turnaround commonly ranges from about one to three weeks after the testing laboratory receives an acceptable specimen. Delays can occur while locating the block, obtaining authorization, repeating extraction, or requesting another sample.
Costs can be several thousand U.S. dollars. Coverage depends on diagnosis, stage, assay, payer policy, and whether the result is considered medically necessary. Manufacturer assistance programs may exist, but financial arrangements should not replace an evidence-based decision about whether the test is appropriate.
Using the Result in a Treatment Plan
The result should be discussed with the clinician who understands both the assay and the cancer. A pathology or molecular tumor board may help when the report conflicts with other findings or the evidence is complex.
For early breast cancer, the discussion may compare the estimated recurrence risk with and without chemotherapy, taking age, menopausal status, lymph nodes, tumor size, grade, and patient preferences into account. A low score can support omitting chemotherapy in an appropriate population; it does not justify skipping endocrine therapy when endocrine therapy is indicated.
For prostate cancer, the score may refine an active-surveillance or treatment conversation. It should be integrated with MRI, PSA density, biopsy findings, stage, and life expectancy. A high molecular risk does not automatically select one treatment modality.
For melanoma, thyroid, or less established uses, ask whether acting on the result is supported by guidelines or prospective evidence. A test may provide additional prognostic information without proving that more imaging or more aggressive treatment improves outcomes.
Do not compare scores from repeat testing as if they were a standard monitoring marker unless the assay was designed for serial use. Expression can differ between a primary tumor and metastasis, between two biopsy sites, or before and after therapy. Most recurrence panels are one-time decision tools, not surveillance tests.
Keep the complete report with the pathology records. The document should identify the specimen, assay version, score, category, intended-use statement, limitations, and clinical interpretation. If the result is close to a cutoff, the continuous value and clinical context deserve more attention than the category label alone.
The strongest use of an RNA expression panel is to reduce uncertainty at a defined treatment crossroads. It adds one layer of tumor biology; it does not replace pathology, staging, patient goals, or an individualized risk-benefit discussion.
References
- Multi-gene expression assays in breast cancer: a literature review 2025 (Review)
- Gene Expression Assays to Tailor Adjuvant Endocrine Therapy for HR+/HER2- Breast Cancer 2024 (Review)
- Selecting postoperative adjuvant systemic therapy for early-stage breast cancer using gene expression assays: an updated assessment and systematic review 2024 (Systematic Review)
- Management of melanoma: can we use gene expression profiling to help guide treatment and surveillance? 2024 (Review)
- Predictive and prognostic biomarkers in urological tumours 2024 (Review)
- Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update 2022 (Guideline)
Disclaimer
RNA expression panel results are assay-specific and should be interpreted by the treating oncology team with the pathology, stage, treatment history, overall health, and patient preferences. A low score does not guarantee that cancer will not recur, and a high score does not prove that recurrence will occur or that a particular treatment will help. Do not change cancer treatment or surveillance based only on a general explanation of an expression score.
